i2O Therapeutics
NEWS
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
Thursday’s FDA advisory committee rejection is the latest regulatory defeat for the company’s drug-device combo. The panel found that the benefits of the treatment did not outweigh its risks.
JOBS
IN THE PRESS